Cure Today

‘Key Signs’ of Cytokine Release Syndrome to Know

For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving. It’s important for patients receiving bispecific antibodies for lymphoma or ...
Medical Xpress

Wearable devices may help detect cytokine release syndrome earlier in patients receiving CAR-T therapy

Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of ...
Yahoo Finance

FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)

INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...
Pulse 2.0

CytoAgents: Cytokine Release Syndrome Treatment Company Receives Third Grant From NIH

CytoAgents – a clinical-stage biotechnology company dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS) – announced that it has been awarded a $2 million ...
Business Wire

CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release Syndrome in CAR T-cell Therapy

PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has initiated ...
BioTechniques

Cloaked CAR-NK cells avoid cytokine release syndrome

Immune-evading CAR-NK cells maintained a population in mice long enough to eliminate cancer whilst avoiding cytokine release syndrome. Massachusetts Institute of Technology (MIT) and Harvard Medical ...
Business Wire

CytoAgents Receives Third Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome

PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc. (the Company), a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), ...
Monthly Prescribing Reference

Avtozma IV Gains Approval for Cytokine Release Syndrome

Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
ascopubs.org

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses

Unmet Social Needs Among Cancer Survivors Who Were Concomitant Caregivers: A Cross-Sectional Analysis of the Health Information National Trends Survey Talquetamab is a G protein–coupled receptor class ...
GEN

Immuno-Safety Evaluation: Translational Cytokine Release Syndrome Assay for CAR T Development

A significant concern with CRS in drug development is its unpredictability, both in terms of when and how severely it will manifest in humans. Traditional preclinical models, such as non-human ...
The American Journal of Managed Care

Best Practices for Managing Cytokine Release Syndrome and ICANS with Bispecific Antibodies in Follicular Lymphoma

Discover effective strategies for monitoring and managing CRS toxicity and ICANS, enhancing patient care and reducing burdens in treatment. Bispecific antibodies have transformed the treatment ...
BIOENGINEER

Liver Injury After CAR T-Cell Therapy May Be Driven by Cytokine Storm, Landmark Analysis Finds

A pharmacovigilance analysis of nearly five million adverse-event reports finds that liver injury after CAR T-cell therapy is ...